ARTICLE | Clinical News
Elagolix: Phase III started
February 15, 2016 8:00 AM UTC
AbbVie began double-blind, placebo-controlled, U.S. Phase III trial to evaluate oral elagolix with or without estradiol/norethindrone acetate in about 400 patients. The trial includes a 6-month extens...